Strategic Timing of Antiretroviral Treatment


HIV Infection

What is the purpose of this trial?


  • To find out if the chance of developing a serious illness or of getting AIDS is less if patients start taking HIV medicines at a time when their cluster-of-differentiation-4 (CD4)+ cell count is still fairly high, instead of waiting until the CD4+ count is at the level where there is good evidence for starting medicines.
  • To learn more about how a strategy of starting HIV medicines early might affect other aspects of care, such as the chances of developing other illnesses or resistance to HIV medicines, the frequency of doctor visits, the cost of medical care, and general health and satisfaction.

Participation Guidelines

18 Years - N/A

Click here for detailed information about who can participate in this trial.

Bristol-Myers Squibb
Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
German Federal Ministry of Education and Research
Gilead Sciences
Medical Research Council (MRC) Clinical Trials Unit -- London, United Kingdom
Merck Sharp & Dohme Corp.
National Cancer Institute (NCI)
National Health and Medical Research Council, Australia
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute of Mental Health (NIMH)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institutes of Health Clinical Center (CC)
NEAT - European AIDS Treatment Network
The Institute for Clinical Research at the Veterans Affairs Medical Center -- Washington, D.C., USA
The Kirby Institute for Infection and Immunity in Society
Tibotec Pharmaceutical Limited
University of Minnesota - Clinical and Translational Science Institute
March 2009
Last Updated:
January 14, 2015
Study HIC#: ID: NCT00867048